ArticleDeutsches Arzteblatt international2017
Community-Acquired Pneumonia in Adults.
Article in Deutsches Arzteblatt international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 65 citations in OpenAlex.
- Management and documentation of pneumonia - a comparison of patients consulting primary care and emergency care.Scandinavian journal of primary health care · 2024Article
- Comparison of outcomes and characteristics of patients admitted to the ICU with COVID-19 and other community-acquired pneumonia based on propensity score matching.BMC infectious diseases · 2024Article
- Community-acquired Pneumonia among Elderly Patients Admitted to the Department of Medicine in a Tertiary Care Centre: A Descriptive Cross-sectional Study.JNMA; journal of the Nepal Medical Association · 2023Article
- Bacterial profile and their antimicrobial resistance patterns among patients with community-acquired pneumonia in southwestern Iran.Iranian journal of microbiology · 2023Article
- Non-Adherence in Adult Male Patients with Community-Acquired Pneumonia: Relative Forgiveness of Amoxicillin versus Respiratory Fluoroquinolones.Antibiotics (Basel, Switzerland) · 2023Article
- Outpatient treatment of pneumonia in a setting with and without an infectious disease doctor.Croatian medical journal · 2023Article
- Risk of Acute Respiratory Distress Syndrome in Community-Acquired Pneumonia Patients: Use of an Artificial Neural Network Model.Emergency medicine international · 2023Article
- Doxycycline vs. macrolides in combination with a β-lactam antibiotic for the treatment of community-acquired pneumonia in inpatients.European journal of medical research · 2022Article
- Clinical and economic burden of pneumococcal disease among individuals aged 16 years and older in Germany.Epidemiology and infection · 2022Article
- Clinical profile analysis and nomogram for predicting in-hospital mortality among elderly severe community-acquired pneumonia patients with comorbid cardiovascular disease: a retrospective cohort study.BMC pulmonary medicine · 2022Article
- Neutrophil-lymphocyte ratio as a predictor of adverse outcome in patients with community-acquired pneumonia: A systematic review.Health science reports · 2022Review
- All-cause mortality and disease progression in SARS-CoV-2-infected patients with or without antibiotic therapy: an analysis of the LEOSS cohort.Infection · 2022Article
- Diagnostic Significance of Metagenomic Next-Generation Sequencing for Community-Acquired Pneumonia in Southern China.Frontiers in medicine · 2022Article
- A lightweight deep learning architecture for the automatic detection of pneumonia using chest X-ray images.Multimedia tools and applications · 2022Article
- Adherence to National Antimicrobial Guidelines in Hospitalized Geriatric Patients with Community-Acquired Pneumonia: A Prospective Observational study in a Malaysian Hospital.Antibiotics (Basel, Switzerland) · 2021Article
- Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin.Infectious diseases and therapy · 2021Review
- [Community-acquired pneumonia].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2018Review
- Multifaceted Role of Pneumolysin in the Pathogenesis of Myocardial Injury in Community-Acquired Pneumonia.International journal of molecular sciences · 2018Review
- In Reply.Deutsches Arzteblatt international · 2018Article
- Adequate Risk Stratification.Deutsches Arzteblatt international · 2018Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical spectrum of community-acquired pneumonia ranges from infections that can be treated on an outpatient basis, with 1% mortality, to those that present as medical emergencies, with a mortality above 40%.
methodsThis article is based on pertinent publications and current guidelines retrieved by a selective search of the literature.
resultsThe radiological demonstration of an infiltrate is required for the differentiation of pneumonia from acute bronchitis regardless of whether the patient is seen in the outpatient setting or in the emergency room. For risk prediction, it is recommended that the CRB-65 criteria, unstable comorbidities, and oxygenation should be taken into account. Amoxicillin is the drug of choice for mild pneumonia; it should be given in combination with clavulanic acid if there are any comorbid illnesses. The main clinical concerns in the emergency room are the identification of acute organ dysfunction and the management of sepsis. Intravenous beta-lactam antibiotics should be given initially, in combination with a macrolide if acute organ dysfunction is present. The treatment should be continued for 5-7 days. Cardiovascular complications worsen the patient's prognosis and should be meticulously watched for. Structured followup care includes the follow-up of comorbid conditions and the initiation of recommended preventive measures such as antipneumococcal and anti-influenza vaccination, the avoidance of drugs that increase the risk, smoking cessation, and treatment of dysphagia, if present.
conclusionMajor considerations include appropriate risk stratification and the implementation of a management strategy adapted to the degree of severity of the disease, along with the establishment of structured follow-up care and secondary prevention, especially for patients with comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.